Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Passage Bio

Passage Bio
Regional

Passage Bio CEO to Speak at Chardan Genetic Medicines Conference

October 20, 2025October 19, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its president and chief executive officer, Will Chou, M.D., will participate in a panel discussion at the Chardan 9th Annual …

Passage Bio CEO to Speak at Chardan Genetic Medicines Conference Read More

Passage Bio
Regional

Passage Bio to Present at H.C. Wainwright Global Investment Conference

August 29, 2025August 28, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its management team will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, in …

Passage Bio to Present at H.C. Wainwright Global Investment Conference Read More
Passage Bio
Regional

Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027

August 14, 2025August 12, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) announced second-quarter 2025 results and reported key advancements in its upliFT-D clinical trial, including completion of dosing in the second cohort of …

Passage Bio Reports Strong Progress in FTD-GRN Gene Therapy Trial, Extends Cash Runway to 2027 Read More

Passage Bio
Regional

Passage Bio Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Compliance

July 11, 2025July 10, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its Board of Directors has approved a 1-for-20 reverse stock split, set to take effect at 12:01 a.m. Eastern time …

Passage Bio Approves 1-for-20 Reverse Stock Split to Maintain Nasdaq Compliance Read More
Passage Bio
Regional

Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia

June 24, 2025June 23, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …

Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More

Passage Bio
Regional

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025May 16, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared its financial results for the first quarter of 2025, along with updates on its ongoing clinical programs and operational advancements. …

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development Read More
Passage Bio
Regional

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program

March 5, 2025March 4, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy program for frontotemporal dementia (FTD) associated with GRN mutations (FTD-GRN) …

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program Read More

Passage Bio
Regional

Passage Bio to Present at Two Major Investor Conferences

February 27, 2025February 26, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, where management will share updates on the company’s progress and engage with stakeholders.

Passage Bio to Present at Two Major Investor Conferences Read More
Passage Bio
Regional

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment

January 11, 2025January 10, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More
Passage Bio
Regional

Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results

November 14, 2024November 13, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …

Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read More

Posts pagination

1 2 Next

Trending News

  • Wilmington Police Investigate Sunday Evening Shooting on West 6th Street

  • Wilmington Police Investigate Fatal Sunday Afternoon Shooting

  • Overnight Closure Planned for Tacony Street in Philly

  • Penn Medicine Park to Host Halloween ‘Boos & Brews’ Beer Festival

  • Cecil College Invites Future Students to Explore Opportunities at Fall Open House

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Crime scene do not cross signage

Wilmington Police Investigate Sunday Evening Shooting on West 6th Street

October 20, 2025October 20, 2025

Police News

Wilmington Police Investigate Fatal Sunday Afternoon Shooting

October 20, 2025October 20, 2025

Jacques Kula

Levittown Man Arrested in Tullytown on Active Bucks County Warrant

October 19, 2025October 19, 2025

Copyright © 2025 MyChesCo.